Eagle Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.7M
Doctors Paid
4,867
Transactions
6,908
2024 Total
$177,062
Payment Breakdown by Category
Research$13.5M (92.1%)
Consulting$258,781 (1.8%)
Food & Beverage$238,336 (1.6%)
Travel$115,432 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.5M | 211 | 92.1% |
| Honoraria | $368,903 | 125 | 2.5% |
| Consulting Fee | $258,781 | 95 | 1.8% |
| Food and Beverage | $238,336 | 6,174 | 1.6% |
| Charitable Contribution | $160,342 | 21 | 1.1% |
| Travel and Lodging | $115,432 | 277 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,608 | 5 | 0.1% |
Payments by Type
Research
$13.5M
211 transactions
General
$1.2M
6,697 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 1, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLDERABILITY, AND PHARMACOKINETICS OF FULVESTRANT TEST VS. REFERENCE FOLLOWING INTRAMUSCULAR ADMINISTRATION TO THE GLUTEAL MUSCLE IN HEALTHY FEMALE SUBJECTS, PROTOCOL NO. EGL-5 | $9.1M | 0 | 131 |
| STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF FULVESTRANT AFTER IM ADMINISTRATION | $1.9M | 0 | 30 |
| PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETCS OF THREE FORMULATIONS OF FULVESTRANT FOR INJECTABLE SUSPENSION TEST COMPARED TO FASLODEX INJECTION REFERENCE FOLLOWING SINGLE DOSE INTRAMUSCU | $1.7M | 0 | 8 |
| TO ASSESS THE POTENTIAL NEUROPROTECTIVE EFFECTS AND SAFETY OF INTRANASAL ADMINISTRATION OF DANTROLENE IN A 5XFAD ALZHEIMER S DISEASE MOUSE MODEL. | $277,170 | 0 | 5 |
| INVESTIGATION OF REMIMAZOLAM IN CHILDREN UNDERGOING SEDATION FOR MEDICAL PROCEDURES | $202,847 | 0 | 10 |
| EAGL11.5860 Bendamustine HCL BDM | $64,808 | 0 | 12 |
| A PILOT TRIAL TO DEMONSTRATE THE FEASIBILITY OF USING DANTROLENE TO STUDY RYR2 INHIBITION TO PREVENT VENTRIBULAR ARRHYTHMIAS - AHA STRATEGICALLY FOCUSED RESEARCH NETWORK | $59,655 | 0 | 1 |
| STUDY IS TO EVALUATE RYANODEX AS A TREATMENT FOR TRAUMATIC BRAIN INJURY TBI IN A RODENT TBI MODEL | $56,400 | 0 | 2 |
| EVALUATION OF THE EFFICACY OF RYANODEX AS A TREATMENT FOR TRAUMATIC BRAIN INJURY IN A RODENT MODEL | $44,454 | 0 | 1 |
| MULTI-ARM OPTIMIZATION OF STROKE THROMBOLYSIS MOST | $36,000 | 0 | 1 |
| ACADEMIC STUDY | $32,539 | 0 | 2 |
| EAGL11.5860 Bendamustine HCL (BDM) | $12,812 | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Larry Norton, Md, MD | Medical Oncology | New York, NY | $1,500 | $0 |
| Sandra Brown, Crnp, CRNP | Nurse Practitioner | Huntsville, AL | $1,486 | $0 |
| Maisam Abu-El-Haija, M.d, M.D | Pediatrics | Cincinnati, OH | $1,400 | $0 |
| Alexandra Carey, Md, MD | Pediatric Gastroenterology | Boston, MA | $1,200 | $0 |
| John Oppenheimer, Md, MD | Allergy | Cedar Knolls, NJ | $1,200 | $0 |
| Jacob Brandenburg, M.d, M.D | Anesthesiology | Salt Lake City, UT | $1,100 | $0 |
| Dr. Guy Young, M.d, M.D | Pediatric Hematology-Oncology | Bozeman, MT | $1,000 | $0 |
| Dennis Moore, Md, MD | Hematology & Oncology | Wichita, KS | $850.00 | $0 |
| Bassam Mattar, Md, MD | Hematology & Oncology | Wichita, KS | $850.00 | $0 |
| Shaker Dakhil, Md, MD | Hematology & Oncology | Wichita, KS | $850.00 | $0 |
| Quoc Truong, Md, MD | Internal Medicine | Wichita, KS | $850.00 | $0 |
| Phu Truong, Md, MD | Hematology & Oncology | Wichita, KS | $850.00 | $0 |
| Dr. Stanley Nabrinsky, Md, MD | Hematology & Oncology | Elgin, IL | $850.00 | $0 |
| Dr. Joseph Moore, Md, MD | Internal Medicine | Wichita, KS | $850.00 | $0 |
| Tarek Chidiac, Md, MD | Medical Oncology | Columbus, OH | $850.00 | $0 |
| Travis Koeneke, Md, MD | Internal Medicine | Manhattan, KS | $850.00 | $0 |
| Rajat Malhotra, Md, MD | Hematology & Oncology | Arlington Heights, IL | $850.00 | $0 |
| Dr. John Dibaise, M.d, M.D | Gastroenterology | Scottsdale, AZ | $800.00 | $0 |
| Andrew (Andrzej) Ukleja, M.d, M.D | Gastroenterology | Weston, FL | $800.00 | $0 |
| Phillip Lieberman, Md, MD | Allergy & Immunology | Memphis, TN | $800.00 | $0 |
| Dr. Daron Street, M.d, M.D | Gynecologic Oncology | Tulsa, OK | $722.64 | $0 |
| Keira Mason, Md, MD | Pediatric Anesthesiology | Boston, MA | $670.07 | $0 |
| Rajesh Lalla, Dds, DDS | General Practice | Farmington, CT | $666.00 | $0 |
| Dr. Udaya Padakandla, Md, MD | Critical Care Medicine | Dallas, TX | $631.48 | $0 |
| Dr. Erica Mayer, Md Mph, MD MPH | Medical Oncology | Boston, MA | $600.00 | $0 |
Ad
Top Products
- NOVEL FULVESTRANT FORMULATION $1.9M
- Fulvestrant $1.7M
Associated Products (7)
- NOVEL FULVESTRANT FORMULATION $1.9M
- Fulvestrant $1.7M
- Ryanodex $625,640
- Ryanodex Single Use Only - 250ml $276,492
- Bendamustine HCL $77,620
- Argatroban 1 vial in one carton $36,000
- PEMFEXY $25,827
Payment Categories
- Food & Beverage $238,336
- Consulting $258,781
- Travel & Lodging $115,432
- Research $13.5M
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. has made $14.7M in payments to 4,867 healthcare providers, recorded across 6,908 transactions in the CMS Open Payments database. In 2024, the company paid $177,062. The top product by payment volume is NOVEL FULVESTRANT FORMULATION ($1.9M).
Payments were distributed across 124 medical specialties. The top specialty by payment amount is Anesthesiology ($400,993 to 1,395 doctors).
Payment categories include: Food & Beverage ($238,336), Consulting ($258,781), Research ($13.5M), Travel & Lodging ($115,432).
Eagle Pharmaceuticals, Inc. is associated with 7 products in the CMS Open Payments database, including NOVEL FULVESTRANT FORMULATION, Fulvestrant, and Ryanodex.